SCHEMBL1503548

SCHEMBL1503548

Cc1ccc(CCl)c2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.59
CYP2A6 P11509 3/20 0.46
DAO P14920 1/20 0.42
ALDH1A1 P00352 2/20 0.39
NPBWR1 P48145 1/20 0.39
TSHR P16473 3/20 0.37
PON1 P27169 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
ACHE P22303 1/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
GRIN2B Q13224 1/20 0.33
GRIN2C Q14957 1/20 0.33
GRIN3A Q8TCU5 1/20 0.33
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29558862 0.85 L3MBTL1 (0.44) CYP1A2CYP2A6ALDH1A1TSHRCYP3A4
SCHEMBL2466440 0.85 L3MBTL1 (0.44) CYP1A2CYP2A6ALDH1A1TSHRCYP3A4
SCHEMBL8816153 0.81 CYP1A2 (0.65) CYP1A2CYP2A6DAOALDH1A1TSHR
SCHEMBL9519292 0.79 CYP1A2 (0.62) CYP1A2CYP2A6DAOALDH1A1TSHR
SCHEMBL7754391 0.79 CYP1A2 (0.62) CYP1A2CYP2A6DAOALDH1A1NPBWR1
SCHEMBL30975074 0.79 CYP1A2 (0.62) CYP1A2CYP2A6DAOALDH1A1TSHR
SCHEMBL19676944 0.77 CYP1A2 (0.59) CYP1A2CYP2A6DAOALDH1A1NPBWR1
SCHEMBL2454747 0.77 CYP1A2 (0.59) CYP1A2CYP2A6DAOALDH1A1NPBWR1
SCHEMBL3914647 0.77 CYP1A2 (0.59) CYP1A2CYP2A6DAOALDH1A1TSHR
SCHEMBL3078325 0.77 CYP1A2 (0.59) CYP1A2CYP2A6DAOALDH1A1NPBWR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117777411-A Crosslinked methylene aromatic hydrocarbon high polymer and synthesis method thereof 乐山师范学院 2024-03-29 CN claimed
CN-100596295-C 1-methyl-4[4-(N,N-p-methylphenyl amido)styryl]naphthyl and method of manufacturing the same and application thereof UNIV TIANJIN 2010-03-31 CN claimed
CN-101108808-A 1-methyl-4[4-(N,N-p-methylphenyl amido)styryl]naphthyl and method of manufacturing the same and application thereof UNIV TIANJIN (CN) 2008-01-23 CN claimed
US-4152352-A PRODUCTION OF ARYLPYRUVIC ACIDS RHONE-POULENC INDUSTRIES (FR) 1979-05-01 US claimed
CN-121850824-A Preparation method of 1, 4-dimethylnaphthalene 湖北迪赛鸿宇新材料技术有限公司 2026-04-14 CN disclosed
CN-117777411-A Crosslinked methylene aromatic hydrocarbon high polymer and synthesis method thereof 乐山师范学院 2024-03-29 CN disclosed
US-9266848-B2 4-alkoxy-N-(2-hydroxycarbamoyl-2-piperidinyl-ethyl)-benzamide compounds as selective TACE-inhibitors for the treatment of inflammatory diseases GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-02-23 US disclosed
EP-2477969-B1 4-ALKOXY-N-(2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL)-BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES. GALDERMA RES & DEV (FR) 2013-10-23 EP disclosed
US-8329727-B2 Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment GILEAD SCIENCES, INC. (US) 2012-12-11 US disclosed
US-20120226033-A1 4-ALKOXY-N- (2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL) -BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-09-06 US disclosed
EP-2477969-A1 4-ALKOXY-N- (2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL) -BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES Galderma Research & Development (FR) 2012-07-25 EP disclosed
WO-2011033010-A1 4-ALKOXY-N- (2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL) -BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-03-24 WO disclosed
US-20070244148-A1 Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2007-10-18 US disclosed
US-20070244148-A1 Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2007-10-18 US disclosed
EP-1268494-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS Merck Frosst Canada & Co. (CA) 2003-01-02 EP disclosed
US-6498151-B2 PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS MERCK FROSST CANADA & CO. (CA) 2002-12-24 US disclosed
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors MERCK FROSST CANADA LTD. (CA) 2002-07-11 US disclosed
WO-2001070753-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-09-27 WO disclosed
US-4576809-A COBALT/II/COMPOUND, CARBON MONOXIDE, HYDROXIDE, SULFUR COMPOUND RHONE-POULENC SPECIALITIES CHIMIQUES (FR) 1986-03-18 US disclosed
US-4152352-A PRODUCTION OF ARYLPYRUVIC ACIDS RHONE-POULENC INDUSTRIES (FR) 1979-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244148-A1 Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment ZC3HAV1, TPMT, DPP4 CYP1A2 336/4885CYP2A6 177/4885DAO 823/4885
US-20120226033-A1 4-ALKOXY-N- (2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL) -BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES TPSAB1, CTSB, TPSB2 CYP1A2 257/4885CYP2A6 826/4885DAO 668/4885
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors PTPRF, PTPRS, PTPRO CYP1A2 2543/4885CYP2A6 408/4885DAO 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.